ADVAXIS INC (ADXS)

Common Stock

0.155  -0.08 (-35.42%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADXS. ADXS was compared to 588 industry peers in the Biotechnology industry. ADXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADXS is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

ADXS had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -37.01%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ADXS does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -581.85%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ADXS has more shares outstanding
There is no outstanding debt for ADXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ADXS has an Altman-Z score of -9.92. This is a bad value and indicates that ADXS is not financially healthy and even has some risk of bankruptcy.
ADXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.92
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 7.03 indicates that ADXS has no problem at all paying its short term obligations.
A Quick Ratio of 7.03 indicates that ADXS has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 7.03
Quick Ratio 7.03

More info and screens

2

3. Growth

3.1 Past

ADXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.75%, which is quite impressive.
The Revenue has grown by 1198.00% in the past year. This is a very strong growth!
ADXS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -72.51% yearly.
EPS 1Y (TTM)58.75%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q77.78%
Revenue 1Y (TTM)1198%
Revenue growth 3Y-72.51%
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

ADXS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.00% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y59.87%
EPS Next 2Y28.29%
EPS Next 3Y18.07%
EPS Next 5Y10%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.27

4.3 Compensation for Growth

ADXS's earnings are expected to grow with 18.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.29%
EPS Next 3Y18.07%

More info and screens

0

5. Dividend

5.1 Amount

ADXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVAXIS INC

NASDAQ:ADXS (12/23/2021, 10:39:10 AM)

0.155

-0.08 (-35.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap22.57M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.01%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -581.85%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.03
Quick Ratio 7.03
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.75%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y59.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1198%
Revenue growth 3Y-72.51%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y